Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction

Mostrar otras versiones (1)

Pompe disease results from acid α-glucosidase (GAA) deficiency, and enzyme replacement therapy (ERT) with recombinant human (rh) GAA has clinical benefits, although its limitations include the short half-life of GAA and the formation of antibody responses. The present study compared the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sang-oh, Ronzitti, Giuseppe, Arnson, Benjamin, Leborgne, Christian, Li, Songtao, Mingozzi, Federico, Koeberl, Dwight
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363303/
https://www.ncbi.nlm.nih.gov/pubmed/28344998
http://dx.doi.org/10.1016/j.omtm.2016.12.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363303/
https://www.ncbi.nlm.nih.gov/pubmed/28344998
http://dx.doi.org/10.1016/j.omtm.2016.12.010

Ejemplares similares